Pharmaceutical and biotech contract development and manufacturing organization Almac recently brought together a group of pharmaceutical suppliers, packagers, and potential customers to distill the current thinking regarding the issues of patient compliance and drug counterfeiting.
Called “Compliance & Counterfeiting—Ensuring your drug product reaches the patient,” the event took place May 16 in Audubon, PA. Among the morning speakers at the conclave was Sr. Dir. Thomas Grinnan, Senior Director Global Patient Adherence, MWV. He talked about insights gleaned from research examining clinical patient compliance using various forms of packaging.
After a tour of Almac’s facility, and lunch, the afternoon sessions began. The last speaker of the afternoon was Mary Foster, Chair Expert Committee, Packaging, Storage and Distribution of Drug Products, U.S. Pharmacopoeia. She emphasized the importance of industry participation in USP committees that have to do with the pharmaceutical supply chain, and asked for volunteers to help craft, and comment on, USP language on the subject.
Almac's Pharmaceutical Development Services provide pharmaceutical customers with early-stage development, clinical trial manufacture, scale-up, and a host of other services.
For more content about Almac, please visit this link and click on the headline(s) of your choice.
![“Another key [UDI] benefit, because we're calling that product by the same name across the healthcare supply chain… rich and robust data that we can access around supply consumption and utilization rates. One of the buzz terms we've heard during the COVID-19 crisis was what's my burn rate? How fast am I going through gowns, masks, gloves?” – Mike Schiller, Senior Director at AHRMM](https://img.healthcarepackaging.com/files/base/pmmi/all/image/2020/08/UDI.5f4d326e41d53.png?auto=format&fit=crop&h=146&w=340)
